Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beam Therapeutics ( (BEAM) ) has provided an announcement.
On January 31, 2026, Beam Therapeutics Inc. announced that board member Dr. Carole Ho had submitted her resignation from the company’s Board of Directors, effective February 27, 2026. The company noted that Dr. Ho’s departure was not due to any disagreement regarding Beam’s operations, policies, or practices, suggesting an orderly governance transition rather than a sign of internal conflict for stakeholders to worry about.
The most recent analyst rating on (BEAM) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.
Spark’s Take on BEAM Stock
According to Spark, TipRanks’ AI Analyst, BEAM is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, very large losses, and negative cash flows). Technicals are constructive with strong trend and positive MACD, but overbought RSI adds near-term risk. Corporate events are a meaningful positive (extended runway and regulatory/clinical progress), while valuation support is limited due to losses and a negative P/E.
To see Spark’s full report on BEAM stock, click here.
More about Beam Therapeutics
Average Trading Volume: 1,902,815
Technical Sentiment Signal: Buy
Current Market Cap: $2.73B
For a thorough assessment of BEAM stock, go to TipRanks’ Stock Analysis page.